Innovative Alzheimer's Treatment with GAL201

Gali Medix Therapeutics presented data at the International Conference on Alzheimer's and Parkinson's Disease, ADPD 2024, showcasing GAL201's potential in treating Alzheimer's disease, with neuroprotective effects and cognitive improvements. GAL201, a small molecule, stands out as it targets toxic alpha-beta oligomers and protofibrils, addressing the underlying causes of the disease. Results revealed GAL201's high affinity to misfolded alpha-beta monomers, preventing neurotoxic forms and preserving dendric spines crucial for synaptic plasticity. Behavioral experiments on AD animal models demonstrated improved cognitive performance comparable to healthy mice post GAL201 injection.